Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 25 of 25 publications.

Kovesdy CP, Layton JB, Thapa BB, Curhan GC, Rangel LM, Farjat AE, Liu F, Johannes CB, Vizcaya D, Oberprieler NG. Reduction in Urinary Albumin-to-Creatinine Ratio (UACR) in people with CKD and type 2 diabetes initiating finerenone: a comedication subgroup analysis from the FOUNTAIN platform. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 24, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):559.

Kovesdy CP, Layton JB, Thapa BB, Curhan GC, Rangel LM, Farjat AE, Liu F, Johannes CB, Vizcaya D, Oberprieler NG. Reduction in Urinary Albumin-to-Creatinine Ratio (UACR) in people with CKD and type 2 diabetes initiating finerenone: a CKD stage subgroup analysis from the FOUNTAIN platform. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 25, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):559.

Ayoub I, Bensink ME, Zhou X, Wang J, Gong W, Preciado P, Komers R, Inrig JK, Rheault MN, Tachtman H. Patient-reported outcomes in adults with FSGS: sparsentan vs. irbesartan. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):281.

Wadhwani S, Bensink M, Peipert JD, Ayoub I, Preciado P, Garbinsky D, Bennett L, Gong W, Inrig J, Komers R. Patient-reported outcomes in the PROTECT clinical trial comparing sparsentan with irbesartan for IgA nephropathy. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):723.

Stothers Rosenberg S, Ng X, Mansfield C, Poulos C, Peay H, Lee TH, Irony T, Ho M. Adaptation of the WOMAC for use in a patient preference study. Ther Innov Regul Sci. 2023 Jul;57(4):702-11. doi: 10.1007/s43441-023-00510-8

Moss E, Burrell AD, Lee JC, Reichenbach D, Mitchell SE, Yan S, Thiruvillakkat K. Structured literature review of the economic and humanistic burden in kidney allograft loss. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting; November 3, 2022. Orlando, FL. [abstract] J Am Soc Nephrol. 2022 Nov; 33(2002):826.

Greene A, Elmer M, Ludlam S, Shay K, Bentley S, Trennery C, Grimes R, Gater A. Evaluation of the content validity and cross-cultural validity of the Study Participant Feedback Questionnaire (SPFQ). Ther Innov Regul Sci. 2020 Nov;54(6):1522-33. doi: 10.1007/s43441-020-00179-3

Mader G, Purser MF, Mladsi DM, Sanon M, Oberdhan D, Watnick TJ, Seliger SL. Benefit of tolvaptan on time to ESRD for patients with rapidly progressing autosomal dominant polycystic kidney disease (ADPKD): a disease progression model. Poster presented at the 2020 Virtual American Society of Nephrology Kidney Week Conference; October 22, 2020. [abstract] J Am Soc Nephrol. 2020 Oct 22; 31:492.

Mader G, Mladsi DM, Zhou X, Sanon M, Wang J, Willey CJ, Seliger SL. Mortality risk in elderly ESRD patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): study findings using data from the United States Renal Data System. Poster presented at the 2020 Virtual American Society of Nephrology Kidney Week Conference; October 22, 2020. [abstract] J Am Soc Nephrol. 2020 Oct; 31:503-4.

Mazurek M, Halperin JL, Huisman MV, Diener HC, Dubner SJ, Ma CS, Rothman KJ, Healey JS, Teutsch C, Paquette M, Franca LR, Lu S, Bartels DB, Lip GYH. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. Europace. 2020 Jan 1;22(1):47-57. doi: 10.1093/europace/euz278

Gilbertson DT, Rothman KJ, Chertow GM, Bradbury BD, Brookhart MA, Liu L, Winkelmayer WC, Sturmer T, Monda KL, Herzog CA, Ashfaq A, Collins AJ, Wetmore JB. Excess deaths attributable to influenza-like illness in the ESRD population. J Am Soc Nephrol. 2019 Feb;30(2):346-53. doi: 10.1681/ASN.2018060581

Byrom B, Gwaltney C, Slagle A, Gnanasakthy A, Muehlhausen W. Measurement equivalence of patient-reported outcome measures migrated to electronic formats: a review of evidence and recommendations for clinical trials and bring your own device. Expert commentary. Ther Innov Regul Sci. 2018 Aug 29. doi: 10.1177/2168479018793369

Odom D, McLeod L, Sherif B, Nelson L, McSorley D. Longitudinal modeling approaches to assess the association between changes in 2 clinical outcome assessments. Ther Innov Regul Sci. 2018 May;52(3):306-12. doi: 10.1177/2168479017731584

Deal LS, DeMuro C, DiBenedetti D, Lewis S. Development of the observable behaviors of autism spectrum disorder scale. Ther Innov Regul Sci. 2017 May 1;51(3):372-9. doi: 10.1177/2168479016680258

Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ, Bradbury BD, Collins AJ. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform. J Am Soc Nephrol. 2016 Oct;27(10):3129-38. doi: 10.1681/ASN.2015111232

Huisman MV, Ma CS, Diener HC, Dubner SJ, Halperin JL, Rothman KJ, Teutsch C, Schoof N, Kleine E, Bartels DB, Lip GY. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) phase I cohort. Europace. 2016 Sep;18(9):1308-18. doi: 10.1093/europace/euw073

Williams V, McLeod L, Nelson L. Advances in the evaluation of longitudinal construct validity of clinical outcome assessments. Ther Innov Regul Sci. 2015 Nov;49(6):805-12. doi: 10.1177/2168479015609103

O'Donohoe P, Lundy JJ, Gnanasakthy A, Greene A. Considerations for requiring subjects to provide a response to electronic patient-reported outcome instruments. Ther Innov Regul Sci. 2015 Nov;49(6):792-6. doi: 10.1177/2168479015609647

Gnanasakthy A, DeMuro C. Overcoming organizational challenges of integrating patient-reported outcomes in oncology clinical trials. Ther Innov Regul Sci. 2015 Oct;49(6):822-30. doi: 10.1177/2168479015608413

Gnanasakthy A, Sadrick A, Eghbal-Ahmadi M, DeMuro C. Promotion of patient-reported outcome label claims based on nonprimary endpoints. Ther Innov Regul Sci. 2014 Sep;48(5):557-63.

Gnanasakthy A, DeMuro-Mercon CJ, Clark MJ, Mordin MM, Thomas S. Role of patient-reported outcome measures in the assessment of central nervous system agents. Ther Innov Regul Sci. 2013;47(5):613-8.

Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda J, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011 Oct 1;13(10):1375-85.

Egbuna O, Cheung AM, Siddhanti S, Wang A, Daizadeh N, Anthony MS. Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification. J Am Soc Nephrol. 2010;21:640A-1A.

Earnshaw SR, Graham CN, Irish WD, Sato R, Schnitzler MA. Lifetime cost-effectiveness of calcineurin inhibitor withdrawal after de novo renal transplantation. J Am Soc Nephrol. 2008 Sep 1;19(9):1807-16.

Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Rothman KJ, Fischer M, Mehta J, Winkelmayer WC. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol. 2008 Jul 1;19(7):1389-95.